-
Product Insights
Myopia – Drugs In Development, 2023
Global Markets Direct’s, ‘Myopia - Drugs In Development, 2023’, provides an overview of the Myopia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myopia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SHJ-002 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHJ-002 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SHJ-002 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: SHJ-002 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SHJ-002 in Myopia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHJ-002 in Myopia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SHJ-002 in MyopiaDrug Details:SHJ-002 is under development for the treatment of myopia in pediatrics...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etrolizumab in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Etrolizumab in Ulcerative Colitis Drug Details:Etrolizumab (RG-7413) is under development for the treatment of ulcerative colitis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SOT-102 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SOT-102 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SOT-102 in Gastric Cancer Drug Details:SON-102 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SHJ-002
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SHJ-002 Drug Details SHJ-002 is under development for the treatment of myopia in pediatrics...